Recombinant CCR4 (Mogamulizumab Biosimilar) 抗体
The 兔 Chimeric anti-CCR4 (Mogamulizumab Biosimilar) antibody is suitable to detect CCR4 (Mogamulizumab Biosimilar) in samples from 人. It has been validated for Dep.
1 image
产品编号 ABIN7072382
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant CCR4 (Mogamulizumab Biosimilar) 抗体 (ABIN7072382)
抗原
CCR4 (Mogamulizumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
兔
克隆类型
Chimeric
标记
This CCR4 (Mogamulizumab Biosimilar) antibody is un-conjugated
应用范围
Depletion (Dep)
克隆位点
KW-0761
-
-
原理
- Anti-CCR4 [KW-0761 (Mogamulizumab)], Rabbit IgG, kappa
-
特异性
- This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.
-
产品特性
-
Original Species of Ab: Human
Original Format of Ab: IgG1
-
纯化方法
- Protein A affinity purified
-
免疫原
- This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
-
亚型
- IgG kappa
-
-
anti-CCR4 (Mogamulizumab Biosimilar) antibody
Research Grade 适用: 人 FACS 宿主: Humanized Monoclonal unconjugated
-
-
应用备注
- The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8 % and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action, in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.
-
说明
-
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
-
限制
- 仅限研究用
-
-
-
浓度
- 1 mg/mL
-
缓冲液
- PBS with 0.02 % Proclin 300.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
- CCR4 (Mogamulizumab Biosimilar)
-
物质类
- Biosimilar
-
背景
- CD194, CKR-4, CCR-4, CCR4, K5-5
-
UniProt
- P51679
抗原
-
You are here:
